The efficacy of Alfuzosin treatment in patients with prostatism

International Urology and Nephrology

Volumn 33, Issue 3, 2001, Pages 493-497

  Başar, M Murad ^a   Atan, Ali ^a   Özergin, Osman ^a   Yildiz, Müslüm ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Alfuzosin; Alpha 1a adreneceptor antagonist; BPH

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN; QUINAZOLINE DERIVATIVE; ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1A ADRENERGIC RECEPTOR BLOCKING AGENT; ASPARTATE AMINOTRANSFERASE; CREATININE; GLUCOSE; LACTATE DEHYDROGENASE; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLOOD; EVALUATION; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PROSTATE HYPERTROPHY; TREATMENT OUTCOME; URODYNAMICS; ADULT; ANTIGEN DETECTION; ASSAY; BIOCHEMISTRY; BLADDER CAPACITY; BLOOD PRESSURE MEASUREMENT; CLINICAL TRIAL; COMPARATIVE STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; ECHOGRAPHY; HUMAN TISSUE; PROSTATISM; REFERENCE VALUE; RESIDUAL URINE; SERUM; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STUDENT T TEST; SYMPTOM; SYSTOLIC BLOOD PRESSURE; URINARY TRACT DISEASE; URINE FLOWMETER; UROGENITAL SYSTEM PARAMETERS; UROLOGIC EXAMINATION;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; QUINAZOLINES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URODYNAMICS; HUMAN; MIDDLE AGE;

EID: 0035545323     PISSN: 03011623     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1019555020671     Document Type: Article

References (21)

1. The assessment of medical treatment for benign prostatic hyperplasia
2. Finasteride (MK-906) in treatment of benign prostatic hyperplasia
3. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostatic smooth muscle
4. Alpha blockers therapy in benign prostatic hyperplasia
5. Uroselectivity
6. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck
7. Management of benign prostatic hyperplasia
8. Alfuzosin for treatment of benign prostatic hypertrophy
9. Efficacy and safety of sustained release alfuzosin 5 mg in patients with benign prostatic hyperplasia
10. Alfuzosin in the treatment of benign prostatic hyperplasia: Effects on symptom scores, urinary flow rates and residual volume. A multicenter double-blind placebo controlled trial
11. Belgian multicenter clinical study of alfuzosin, a selective alpha-1 blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin group
12. Multicenter observational trial on symptomatic treatment of benign prostatic hyperplasia with alfuzosin: Clinical evaluation of impact on patients' quality of life
13. Clinical uroselectivity of alfuzosin in the treatment of benign prostatic hyperplasia
14. A meta-analysis of the efficacy and tolerability of alpha-1 adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction
15. Alfuzosin
16. Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 12-18 month assessment
17. Long-term treatment of benign prostatic hyperplasia with alfuzosin: A 24-30 month survey
18. Alfuzosin: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in benign prostatic hyperplasia
19. Prostatic alpha adrenoceptors
20. Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin
21. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin